

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Dkt. No.: 11362.0025.DVUS03

(INNS:025--3)

**Prior Application Examiner:** 

Robert A. Zeman

BOX PATENT APPLICATION

Commissioner for Patents Washington, D.C. 20231

Classification Designation:

435-070.210

Prior Group Art Unit: 1645

CERTIFICATE OF EXPRESS MAIL

EL521279522US NUMBER

I hereby certify that this paper or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST

OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to:

Commissioner for Patents, Washington, D.C. 20231.

Signature

## REQUEST FOR FILING CONTINUATION APPLICATION UNDER 37 C.F.R. § 1.53(b)

This is a request for filing a continuation application under Rule 53(b) (37 C.F.R. § 1.53(b)) of co-pending prior application Serial No. 09/379,270 filed August 23, 1999, entitled "HIV-3 RETROVIRUS AND ITS USE."

Enclosed is a copy of the prior application Serial No. 09/379,270 as originally X 1. filed, including specification, claims, drawings, and declaration. The undersigned hereby verifies that the attached papers are a true copy of the prior application as originally filed and identified above, that no amendments (if any) referred to in the declaration filed to complete the prior application introduced new matter therein, and further that this statement was made with the knowledge that willful

ļī. ľ,ħ .4

false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statement may jeopardize the validity of the application or any patent issuing thereon.

- (a) The inventorship is the same as prior Application Serial Nos. 09/379,270 and 08/900,902.
- (b) Deletion of inventor(s). Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. § 1.63(d)(2) and 1.33(b).
- (c) Priority of foreign patent application number EP 88 109 200.1, filed

  June 9, 1988 in the European Patent Office is claimed under 35

  U.S.C. § 119(a)-(e). The certified copy:

is enclosed.

Please charge Deposit Account No. 01-2508/11362.0025.DVUS03 in the amount of \$710.00 to cover the filing fee as calculated below and the fee for any new claims added in the Preliminary Amendment referred to in Clause No. 8 below.

## CLAIMS AS FILED IN THE PRIOR APPLICATION LESS CLAIMS CANCELED BELOW

FOR	NUMBER FILED	NUMBER EXTRA		RATE	FEE
Basic Fee Total Claims Independent Claims	5 - 20 = 1 - 3 =	0	X X	\$18.00 = \$78.00 =	\$710.00 \$0.00 \$0.00 \$-000
Multiple Depende	nt Claim(s)	TOTAL FIL	ING FE	CES:	\$710.00

- 3. Applicant is entitled to Small Entity Status for this application.
  - (a) A small entity statement is enclosed.
- (b) A small entity statement was filed in the prior nonprovisional application and such status is still proper and desired.
- (c) Small entity status is no longer claimed.
- 4. The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 to 1.21 which may be required for any reason relating to this application, or credit any overpayment to Deposit Account No. 01-2508/11362.0025.DVUS03.
- 6. Address all future communications to:

Patricia A. Kammerer HOWREY SIMON ARNOLD & WHITE, LLP 750 Bering Drive Houston, Texas 77057 (713) 787-1400

		The prior application is presently assigned to Innogenetics N.V.
$\boxtimes$	7.	Enclosed is a preliminary amendment. Any additional fees incurred by this
$\boxtimes$	8.	Enclosed is a preliminary amendment. This above and said fee has been
		amendment are included in the check at No. 2 above and said fee has been
		calculated after calculation of claims and after amendment of claims by the
		preliminary amendment.
П	9.	Cancel in this application claims of the prior application before calculating
لــا		the filing fee. (At least one original independent claim must be retained).
	10.	Amend the specification by inserting before the first line the sentence: This is a
	10.	continuation of co-pending application Serial No. filed
$\boxtimes$	11.	Enclosed are formal drawings.
$\boxtimes$	12.	An Information Disclosure Statement (IDS) is enclosed.
$\boxtimes$		(a) PTO-1449.
		(b) Copies of IDS citations.
	13.	Transfer the sequence information, including the computer readable form previously
		submitted in the parent application, Serial No. filed , for use in this
r		application. Under 37 C.F.R. § 1.821(e), Applicant states that the paper copy of
		the sequence listing in this application is identical to the computer readable copy
		in parent application Serial No. filed . Under 37 C.F.R. § 1.821(f),
		Applicant also states that the information recorded in computer readable form is
		identical to the written sequence listing.
	] 14	Other:

HOWREY SIMON ARNOLD & WHITE, LLP 750 Bering Drive Houston, Texas 77057

Date: May 9, 2001

Respectfully submitted,

Patricia A. Kammerer Reg. No. 29,775

Attorney for Assignee INNOGENETICS N.V.